Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Septerna, Inc.

Get SEC filing alerts via email and in your feed for Septerna, Inc.

SEPN

Septerna, Inc.

About Septerna, Inc.

Septerna, Inc. is a biotechnology company focused on innovative GPCR small molecule drug discovery using its proprietary Native Complex Platform. It develops oral therapeutics across multiple areas, including endocrinology, immunology, and metabolic diseases. Its pipeline targets underserved conditions like hypoparathyroidism, autoimmune thyroid disease, and obesity, leveraging structure-based design to create highly selective, potent medicines with potential for improved safety, efficacy, and patient convenience.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Septerna, Inc.

1
1
Septerna, Inc. Septerna Reports $26.5M Revenue and $8.6M Net Loss for Quarter Ending March 31, 2026

Via official filing (AI summary) | 24 days ago | 0 comments

2
1
Septerna, Inc. Septerna Reports $48.9 Million Net Loss and $45.95 Million Revenue for 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Septerna, Inc. Septerna Reports $21.5 Million Revenue for Q3 2025, Achieves Net Income of $8.2 Million

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Septerna, Inc. Septerna Reports Revenue Decline and Increased Losses in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Septerna, Inc. Septerna Reports $21.5 Million Net Loss in Q1 2025, Revenue Declines to $219,000

Via official filing (AI summary) | about 1 year ago | 0 comments